Novartis: EU approves Xolair for self-administration
(CercleFinance.com) - The European Commission has approved Novartis' asthma injectable drug Xolair for self-administration across all indications, the drugmaker said on Thursday.
The European Commission has approved Xolair pre-filled syringes so that patients with severe allergic asthma and chronic spontaneous urticaria can administer their own treatment, the Swiss group said.
Administered via injection every two-to-four weeks, Xolair is an antibody that is designed to target and block immunoglobulin E, minimising allergic inflammatory reactions.
Copyright (c) 2018 CercleFinance.com. All rights reserved.
The European Commission has approved Xolair pre-filled syringes so that patients with severe allergic asthma and chronic spontaneous urticaria can administer their own treatment, the Swiss group said.
Administered via injection every two-to-four weeks, Xolair is an antibody that is designed to target and block immunoglobulin E, minimising allergic inflammatory reactions.
Copyright (c) 2018 CercleFinance.com. All rights reserved.